Q32 Bio (Q32 Bio) Scaled Net Operating Assets : -1.41 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Q32 Bio's operating assets for the quarter that ended in Mar. 2024 was $17.02 Mil. Q32 Bio's operating liabilities for the quarter that ended in Mar. 2024 was $83.42 Mil. Q32 Bio's Total Assets for the quarter that ended in Dec. 2023 was $47.06 Mil. Therefore, Q32 Bio's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was -1.41.

Q32 Bio Scaled Net Operating Assets Historical Data

The historical data trend for Q32 Bio's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Scaled Net Operating Assets Chart

Q32 Bio Annual Data

Trend

Dec21

Dec22

Dec23

Scaled Net Operating Assets

-0.14

-0.52

-0.75

Q32 Bio Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial			-	-	-	-0.86	-1.41

Competitive Comparison of Q32 Bio's Scaled Net Operating Assets

For the Biotechnology subindustry, Q32 Bio's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Scaled Net Operating Assets falls into.

Q32 Bio Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Q32 Bio's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(21.44	-	67.693)	/	61.774
=	-0.75

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	47.057	-	25.617
=	21.44

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	118.533	-	49.424	-	1.416
=	67.693

Q32 Bio's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(17.022	-	83.418)	/	47.057
=	-1.41

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	152.334	-	135.312
=	17.022

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	103.565	-	15.499	-	4.648
=	83.418

Q32 Bio Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.q32bio.com

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024